Rocket Pharmaceuticals Inc’s recently made public that its insider Schwartz Jonathan David unloaded Company’s shares for reported $69109.0 on Feb 25 ’25. In the deal valued at $10.58 per share,6,532 shares were sold. As a result of this transaction, Schwartz Jonathan David now holds 237,638 shares worth roughly $1.38 million.
Then, Schwartz Jonathan David sold 2,754 shares, generating $64,306 in total proceeds. Upon selling the shares at $23.35, the insider now owns 169,659 shares.
Before that, Schwartz Jonathan David sold 2,710 shares. Rocket Pharmaceuticals Inc shares valued at $50,135 were divested by the insider at a price of $18.50 per share. As a result of the transaction, Schwartz Jonathan David now holds 166,949 shares, worth roughly $0.97 million.
BMO Capital Markets initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on March 12, 2025; the price target was $50. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late December with a ‘”an Outperform”‘ rating. Jefferies began covering RCKT with “Buy” recommendation on December 18, 2024. Scotiabank started covering the stock on October 16, 2024. It rated RCKT as “a Sector outperform”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -12.89% to $5.81. Over the last five days, the stock has lost -28.89%. Rocket Pharmaceuticals Inc shares have fallen nearly -53.78% since the year began. Nevertheless, the stocks have fallen -78.43% over the past one year. While a 52-week high of $26.99 was reached on 01/02/25, a 52-week low of $6.26 was recorded on 04/01/25. SMA at 50 days reached $9.46, while 200 days put it at $15.57.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 5.52, which if violated will result in even more drops to 5.23. On the upside, there is a resistance level at 6.38. A further resistance level may holdings at 6.94. The Relative Strength Index (RSI) on the 14-day chart is 23.00, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.52%. Stochastics %K at 7.90% indicates the stock is a buying.
How much short interest is there in Rocket Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rocket Pharmaceuticals Inc stocks on 2025-03-14, dropping by -0.19 million shares to a total of 11.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 11.24 million shares. There was a decline of -1.75%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 02, 2024 when Goldman began covering the stock and recommended ‘”a Neutral”‘ rating along with a $39 price target.
